South Korea
· Delayed Price · Currency is KRW Hanmi Pharm. Statistics
Total Valuation
Hanmi Pharm. has a market cap or net worth of KRW 3.42 trillion. The enterprise value is 3.88 trillion.
| Market Cap | 3.42T |
| Enterprise Value | 3.88T |
Important Dates
The last earnings date was Wednesday, April 30, 2025.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Hanmi Pharm. has 12.68 million shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 12.68M |
| Shares Outstanding | 12.68M |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 20.73% |
| Float | 6.20M |
Valuation Ratios
The trailing PE ratio is 28.17 and the forward PE ratio is 21.15. Hanmi Pharm.'s PEG ratio is 1.44.
| PE Ratio | 28.17 |
| Forward PE | 21.15 |
| PS Ratio | 2.29 |
| PB Ratio | 2.75 |
| P/TBV Ratio | 3.29 |
| P/FCF Ratio | 22.16 |
| P/OCF Ratio | 17.66 |
| PEG Ratio | 1.44 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.51, with an EV/FCF ratio of 25.14.
| EV / Earnings | 31.96 |
| EV / Sales | 2.59 |
| EV / EBITDA | 12.51 |
| EV / EBIT | 18.24 |
| EV / FCF | 25.14 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.40.
| Current Ratio | 1.09 |
| Quick Ratio | 0.63 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 1.60 |
| Debt / FCF | 3.22 |
| Interest Coverage | 8.72 |
Financial Efficiency
Return on equity (ROE) is 12.00% and return on invested capital (ROIC) is 7.79%.
| Return on Equity (ROE) | 12.00% |
| Return on Assets (ROA) | 6.78% |
| Return on Invested Capital (ROIC) | 7.79% |
| Return on Capital Employed (ROCE) | 15.88% |
| Revenue Per Employee | 641.85M |
| Profits Per Employee | 52.07M |
| Employee Count | 2,330 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 2.30 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.97% in the last 52 weeks. The beta is 0.64, so Hanmi Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -16.97% |
| 50-Day Moving Average | 243,430.00 |
| 200-Day Moving Average | 279,945.00 |
| Relative Strength Index (RSI) | 66.81 |
| Average Volume (20 Days) | 62,757 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hanmi Pharm. had revenue of KRW 1.50 trillion and earned 121.32 billion in profits. Earnings per share was 9,566.83.
| Revenue | 1.50T |
| Gross Profit | 817.04B |
| Operating Income | 212.51B |
| Pretax Income | 171.25B |
| Net Income | 121.32B |
| EBITDA | 309.84B |
| EBIT | 212.51B |
| Earnings Per Share (EPS) | 9,566.83 |
Balance Sheet
The company has 193.20 billion in cash and 496.69 billion in debt, giving a net cash position of -303.49 billion or -23,934.30 per share.
| Cash & Cash Equivalents | 193.20B |
| Total Debt | 496.69B |
| Net Cash | -303.49B |
| Net Cash Per Share | -23,934.30 |
| Equity (Book Value) | 1.24T |
| Book Value Per Share | 85,557.97 |
| Working Capital | 63.55B |
Cash Flow
In the last 12 months, operating cash flow was 193.49 billion and capital expenditures -39.26 billion, giving a free cash flow of 154.23 billion.
| Operating Cash Flow | 193.49B |
| Capital Expenditures | -39.26B |
| Free Cash Flow | 154.23B |
| FCF Per Share | 12,162.70 |
Margins
Gross margin is 54.63%, with operating and profit margins of 14.21% and 8.11%.
| Gross Margin | 54.63% |
| Operating Margin | 14.21% |
| Pretax Margin | 11.45% |
| Profit Margin | 8.11% |
| EBITDA Margin | 20.72% |
| EBIT Margin | 14.21% |
| FCF Margin | 10.31% |
Dividends & Yields
This stock pays an annual dividend of 1,250.00, which amounts to a dividend yield of 0.46%.
| Dividend Per Share | 1,250.00 |
| Dividend Yield | 0.46% |
| Dividend Growth (YoY) | 150.00% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 10.35% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 0.54% |
| Earnings Yield | 3.55% |
| FCF Yield | 4.51% |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
Hanmi Pharm. has an Altman Z-Score of 4.61.
| Altman Z-Score | 4.61 |
| Piotroski F-Score | n/a |